| SFDA Approved Use |
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); Age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
DABIFIB 75/110/150 (Dabigatran Etexilate Capsules 75 mg /110 mg /150 mg) Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 13 Aug 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Official Reliable websites use HTTPS
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.